To Our Central Indiana Friends & Neighbors:

You may have seen news this week from Lilly that one of the potential new medicines we’ve been studying to treat Alzheimer’s disease, called solanezumab, did not succeed in the last stage of clinical testing.

Obviously, we’re disappointed. Lilly researchers have been attacking this disease for nearly 30 years, and many people affected by Alzheimer’s are desperate for a medicine that can slow its progression. Right now, there’s no way to slow, cure or prevent this devastating condition that robs people of their memories, their relationships and their lives.

Sola, as we call it, was the most advanced potential new medicine in our Alzheimer’s pipeline — but it’s by no means the only one. Our bench is deep, with seven potential Alzheimer’s medicines in various stages of development.

Lilly’s business is based on science, and it’s never a straight or easy path. But we refuse to give up. Tens of millions of people — including, perhaps, our own parents and grandparents — are counting on us to discover a treatment that someday will make Alzheimer’s dementia preventable.

We know that when one of our pipeline bets doesn’t work out, it’s natural for people in the community — including our own employees — to wonder about the future health of our business, and the impact on the city.

We’ve been a part of this community for 140 years, and we’re committed to our home. Lilly’s business is strong, and our future remains bright. With new medicines launched and potential new medicines in development for cancer, diabetes, autoimmune diseases, migraine and chronic pain — along with the rest of our Alzheimer’s platform — we’re in the early stages of a growth period that will keep our business solid for years to come.

Our Lilly promise is to “make life better.” And on Monday, our colleagues will get back to work in our scientific labs, our manufacturing plants, across our corporate campus and in the offices of health care providers around the world. People are counting on us. And we’ll deliver — for our families, our communities, and someday, for people with Alzheimer’s disease.


John C. Lechleiter
Chairman, President and CEO
Eli Lilly and Company


David A. Ricks
President, Lilly Bio-Medicines
Incoming President and CEO